Product Description
Fluocinolone Acetonide is the acetonide salt form of fluocinolone, a synthetic fluorinated corticosteroid with antiinflammatory, antipruritic and vasoconstrictive properties. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Fluocinolone-acetonide)
Mechanisms of Action: GR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Injection
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Hypertension | Intracranial Hypertension | Papilledema | Headache | Acneiform Eruptions | Dermatitis | Dermatitis, Allergic Contact | Dermatitis, Contact | Dermatitis, Perioral | Drug Eruptions | Folliculitis | Hypertrichosis | Hypopigmentation | Miliaria | Oral Manifestations | Cushing Syndrome | Animal Hypersensitivity | Drug Hypersensitivity | Hypersensitivity, Delayed | Milk Hypersensitivity | Eye Infections, Bacterial | Eye Infections | Eye Infections, Fungal | Hyperglycemia | Carcinogenesis | Keratoconjunctivitis Sicca | Pregnancy Outcomes | Pregnancy, Prolonged | Hypertension, Renal | Edema | Skin Manifestations | Weight Gain | Otitis | Otitis Media | Pneumonia, Bacterial | Pneumonia | Influenza, Human
Known Adverse Events: Acneiform Eruptions | Dermatitis | Dermatitis, Allergic Contact | Dermatitis, Contact | Dermatitis, Perioral | Folliculitis | Hypertrichosis | Hypopigmentation | Miliaria | Psoriasis | Panic Disorder | Pruritus | Ranula
Company: Alimera Sciences
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Other|Uveitis, Posterior|Vision Disorders|Vision, Low
Phase 2: Glioblastoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AL | P3 |
Recruiting |
Vision, Low|Vision Disorders |
2029-12-26 |
|
| 2022-001622-29 | P3 |
Active, not recruiting |
Uveitis, Posterior |
2027-01-24 |
|
| TEM-GBM | P2 |
Active, not recruiting |
Glioblastoma |
2022-10-12 |
|
| CTR20200866 | P3 |
Not yet recruiting |
Other |
None |